Is Endothelial Dysfunction a Therapeutic Target for Peripheral Artery Disease?: PRDM16 is going out on a limb
- PMID: 34166078
- PMCID: PMC8412211
- DOI: 10.1161/CIRCRESAHA.121.319448
Is Endothelial Dysfunction a Therapeutic Target for Peripheral Artery Disease?: PRDM16 is going out on a limb
Keywords: Editorials; endothelial cells; ischemia; peripheral arterial disease; transcription factor.
Conflict of interest statement
DECLARATION OF INTERESTS
HJ is the founder of FloKines Pharma.
Comment on
-
Prdm16 Supports Arterial Flow Recovery by Maintaining Endothelial Function.Circ Res. 2021 Jun 25;129(1):63-77. doi: 10.1161/CIRCRESAHA.120.318501. Epub 2021 Apr 27. Circ Res. 2021. PMID: 33902304 Free PMC article.
References
-
- Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An update on methods for revascularization and expansion of the tasc lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (tasc ii): The tasc steering committee. Catheter Cardiovasc Interv. 2015;86:611–625 - PubMed
-
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB, Group TIW. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81–157 - PubMed
-
- Virani SS, Alonso A, Aparicio HJ, et al.Heart disease and stroke statistics-2021 update: A report from the american heart association. Circulation. 2021;143:e254–e743 - PubMed
-
- Korshunov VSA. Arteriogenesis and collateral formation. Panvascular medicine. 2015:167–189.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
